|
Volumn 49, Issue 4, 2000, Pages 611-620
|
Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: Results of a phase II clinical trial
a a a a a a a a a a a |
Author keywords
Acute lung injury; Adult respiratory distress syndrome; Infection; Multiple organ dysfunction syndrome; Neutrophils; Pharmacodynamics; Pharmacokinetics; Safety
|
Indexed keywords
MONOCLONAL ANTIBODY CD 18;
RECOMBINANT ANTIBODY;
UNCLASSIFIED DRUG;
ADULT;
ANTIBODY PRODUCTION;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG SAFETY;
GLASGOW COMA SCALE;
HEMORRHAGIC SHOCK;
HUMAN;
MAJOR CLINICAL STUDY;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RESUSCITATION;
TREATMENT OUTCOME;
|
EID: 0033778907
PISSN: 00225282
EISSN: None
Source Type: Journal
DOI: 10.1097/00005373-200010000-00007 Document Type: Conference Paper |
Times cited : (40)
|
References (25)
|